Table 1. Descriptive characteristics of patients at hospital admission.
| Available data (n) | Tocilizumab during hospitalization (n = 122) | No Tocilizumab (n = 149) | p1 | |
|---|---|---|---|---|
| Age, years, median (IQR) | 271 | 63 (54–72) | 63 (53–74) | 0.813 |
| Male sex, % | 271 | 91 (74.6%) | 114 (76.5%) | 0.823 |
| Days from symptoms onset, median (IQR) | 124 | 7.0 (3.5–9.1) | 6.2 (3.3–8.1) | 0.661 |
| Weeks from COVID19 onset in Italy, median (IQR) | 271 | 4.1 (3.3–4.8) | 2.9 (2.1–4.1) | 0.000 |
| BMI, kg/m2, median (IQR) | 114 | 28.1 (25.3–31.2) | 26.7 (24.4–29.7) | 0.133 |
| SOFA score, median (IQR) | 260 | 3 (2–4) | 1 (0–4) | 0.000 |
| Respiratory rate, median (IQR) | 199 | 25 (20–30) | 20 (17–24) | 0.000 |
| pH, median (IQR) | 222 | 7.5 (7.4–7.5) | 7.5 (7.4–7.5) | 0.223 |
| PaCO2, mmHg, median (IQR) | 222 | 35.9 (32.6–39.9) | 36.5 (33.2–39.9) | 0.531 |
| PaO2, mmHg, median (IQR) | 222 | 62.0 (55.7–71.2) | 65.0 (56.5–77.2) | 0.158 |
| SaO2, mmHg, median (IQR) | 221 | 93.3 (90.9–95.2) | 94.0 (90–95.9) | 0.688 |
| PaO2/FiO2, mmHg, median (IQR) | 207 | 164 (98–249) | 279 (181–332) | 0.000 |
| White blood cells, c/mm3, median (IQR) | 244 | 6185 (5150–8338) | 6040 (4950–8575) | 0.902 |
| Hemoglobin, g/dL, median (IQR) | 245 | 13.3 (12.2–14.1) | 13.3 (11.4–14.4) | 0.967 |
| Lymphocytes, c/mm3, median (IQR) | 145 | 1000 (700–2200) | 1400 (900–2900) | 0.048 |
| Platelets, x 109, median (IQR) | 244 | 215 (166–266) | 202 (148–271) | 0.623 |
| Bilirubin, mg/dL, median (IQR) | 233 | 0.6 (0.5–0.8) | 0.6 (0.5–0.8) | 0.375 |
| Creatinine, mg/dL, median (IQR) | 244 | 0.8 (0.7–1.1) | 0.9 (0.7–1.1) | 0.697 |
| Aspartate aminotransferase, IU/L, median (IQR) | 244 | 35 (22–59) | 30 (20–44) | 0.043 |
| Creatine kinase, IU/L, median (IQR) | 242 | 126 (60–260) | 101 (50–256) | 0.335 |
| D-dimer, mg/mL, median (IQR) | 242 | 1150 (745–2133) | 1405 (625–2565) | 0.628 |
| Lactate dehydrogenase, IU/L, median (IQR) | 243 | 628 (533–782) | 531 (419–790) | 0.001 |
| C-reactive protein, mg/dL, median (IQR) | 244 | 12.3 (5.6–17.7) | 6.7 (3.0–16.1) | 0.002 |
| Interleukin-6, pg/mL, median (IQR) | 167 | 202 (109–443) | 194 (57–366) | 0.275 |
| Procalcitonin, ng/mL, median (IQR) | 168 | 0.1 (0.1–0.3) | 0.2 (0.1–2) | 0.007 |
| Troponin, ng/L, median (IQR) | 105 | 12 (12–21) | 12 (12–27) | 0.876 |
| Fibrinogen, mg/dL, median (IQR) | 141 | 647 (509–733) | 606 (505–709) | 0.419 |
| Use of glucocorticoids, % | 271 | 55 (45.1%) | 23 (15.4%) | 0.000 |
| Use of darunavir/cobicistat, % | 271 | 40 (32.8%) | 78 (52.3%) | 0.002 |
Notes: median (inter-quartile range) were reported for quantitative variables and n (%) were reported for categorical variables.
1 = Wilcoxon rank sum test for quantitative variables and Yates chi-square test for categorical variables.